HONG KONG SAR –
Media OutReach Newswire – 18 March 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) right now hosted the
CTC Marketplace Showcase Event: From Clinical Trials to Fundraising, Licensing Deals and Acquisitions, reinforcing its dedication to accelerating the town’s life and well being tech sector. The occasion introduced collectively 110 trade pioneers, buyers, and company companions for a deep dive into the crucial pillars shaping biotech success—from Hong Kong’s distinctive coverage benefits for innovation and the evolving IPO panorama, to the town’s emergence as a worldwide scientific trial hub.
Health Hope Pharma,
Arthrosi Therapeutics Inc,
Nuance Pharma and
InxMed (Hong Kong) Limited.
With over 300 life and well being tech firms in its ecosystem and robust coverage help from the nation and the HKSAR Government, HKSTP is uniquely positioned to drive the following era of medical breakthroughs. Through its end-to-end translational ecosystem, HKSTP accelerates biotech commercialisation by bridging the crucial hole from lab discovery to world market entry—delivering world-class infrastructure, strategic funding, and knowledgeable regulatory steering.
As a strategic catalyst, HKSTP actively connects innovators with top-tier Principal Investigators (PIs), main scientific centres, and institutional buyers, serving to to de-risk improvement pathways, streamline regulatory approvals, and fast-track scientific trials for transformative development.
“At HKSTP, we recognise that a great idea is only the beginning. The real challenge is navigating the long and complex journey from lab to clinic, from concept to cure,” mentioned
Terry Wong, CEO of HKSTP, in his opening remarks. “Today’s CTC Marketplace represents the physical embodiment of our execution strategy. Our mission is to connect, collaborate, and accelerate, because every step forward brings us closer to the patients and communities who depend on our innovations.”
Health Hope Pharma is a Hong Kong-headquartered late-stage scientific oncology biopharma, specialising in novel oral anti-cancer medication in direction of a safer and extra handy different to standard intravenous remedy. Prof Dennis Lam, Founder of Health Hope Pharma, shared his expertise in securing a significant licensing settlement with world biopharmaceutical chief Gilead Sciences, with a possible worth of as much as USD 82.5 million for HHP, together with milestone funds.
Arthrosi Therapeutics Inc. is a US-based clinical-stage biotechnology firm devoted to growing remedy choice aimed at reducing uric acid ranges and lowering joint harm for individuals dwelling with gout. Dr Shunqi Yan, Co-founder and COO of Arthrosi Therapeutics, joined nearly and shared the corporate’s exceptional success in attaining USD 153 million in Series E funding and a subsequent acquisition valued at USD 1.5 billion.
Nuance Pharma is an innovation targeted biopharma firm, with late-stage scientific pipeline and industrial stage asset portfolio throughout respiratory, emergency care, iron deficiency anemia and ache administration. Dr Charlie Chen, COO of Nuance Pharma, mentioned how the corporate leveraged the “1+” mechanism to expedite commercialisation in Hong Kong. The Department of Health accepted Ohtuvayre™ in March 2026, marking it as the primary drug concentrating on persistent obstructive pulmonary illness to realize approval underneath this scheme.
InxMed (Hong Kong) Limited is concentrated on addressing a key problem in most cancers remedy: drug resistance stemming from tumor protection mechanisms. The firm formally submitted its IPO utility to the Hong Kong Stock Exchange in August 2025. Mr Francis Cao, Co-founder and COO of InxMed, emphasised the crucial position of fundraising in advancing their analysis, having accomplished 5 rounds of financing that whole over USD 130 million.
Hashtag: #HKSTP
The issuer is solely accountable for the content material of this announcement.
